Prevalence and Clinical Characteristics of HIV Type 1-Infected Patients Receiving Dialysis in Spain: Results of a Spanish Survey in 2006: GESIDA 48/05 Study

End-stage renal diseases (ESRD) are becoming more frequent in HIV-infected patients. In Europe there is little information about HIV-infected patients on dialysis. A cross-sectional multicenter survey in 328 Spanish dialysis units was conducted in 2006. Information from 14,876 patients in dialysis was obtained (81.6% of the Spanish dialysis population). Eighty-one were HIV infected (0.54%; 95% CI, 0.43-0.67), 60 were on hemodialysis, and 21 were on peritoneal dialysis. The mean (range) age was 45 (28-73) years. Seventy-two percent were men and 33% were former drug users. The mean (range) time of HIV infection was 11 (1-27) years and time on dialysis was 4.6 (0.4-25) years. ESRD was due to glomerulonephritis (36%) and diabetes (15%). HIV-associated nephropathy was not reported. Eighty-five percent were on HAART, 76.5% had a CD4 T cell count above 200 cells, and 73% had undetectable viral load. Thirty-nine percent of patients met criteria for inclusion on the renal transplant (RT) waiting list but only 12% were included. Sixty-one percent had HCV coinfection. HCV-coinfected patients had a longer history of HIV, more previous AIDS events, parenteral transmission as the most common risk factor for acquiring HIV infection, and less access to the RT waiting list (p < 0.05). The prevalence of HIV infection in Spanish dialysis units in 2006 was 0.54% HCV coinfection was very frequent (61%) and the percentage of patients included on the Spanish RT waiting list was low (12%).

This is a copy of an article published in the AIDS Research and Human Retroviruses © 2012 [copyright Mary Ann Liebert, Inc.]; AIDS Research and Human Retroviruses is available online at: http://online.liebertpub.com. Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't;

The study was partially supported by a research grant from the Grupo de Estudio del Sida (GESIDA), Madrid, Spain. The Agencia Ensayos Clínicos del Grupo de Estudio de Sida (AECGESIDA) de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica” (SEIMC) is supported in part by “Plan Nacional sobre el SIDA” of the Spanish Health Ministry. Dr. J.M. Miró received a Research Grant from the “Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS) and the Conselleria de Salut de la Generalitat de Catalunya, Barcelona (Spain).